Edition:
United States

BioScrip Inc (BIOS.OQ)

BIOS.OQ on NASDAQ Stock Exchange Global Select Market

2.22USD
17 Nov 2017
Change (% chg)

$-0.05 (-2.20%)
Prev Close
$2.27
Open
$2.25
Day's High
$2.35
Day's Low
$2.21
Volume
129,715
Avg. Vol
320,656
52-wk High
$3.39
52-wk Low
$0.98

Select another date:

Thu, Oct 5 2017

BRIEF-BioScrip can now dispense & administer radicava treatment option for amyotrophic lateral sclerosis

* BioScrip says can now dispense & administer Radicava (edaravone) treatment option for amyotrophic lateral sclerosis approved by U.S. FDA Source text for Eikon: Further company coverage:

BRIEF-Coliseum Capital reports 14.6 pct stake in Bioscrip

* Coliseum Capital Management LLC reports 14.6 percent stake in Bioscrip Inc as of September 7, 2017 - SEC filing‍​

BRIEF-BioScrip qtrly loss per share $0.26

* Q2 revenue $218.1 million versus I/B/E/S view $220.2 million

BRIEF-Ares Management reports 9.2 pct stake in Bioscrip

* Ares Management reports 9.2 pct stake in Bioscrip as of June 29 - SEC filing

BRIEF-BioScrip announces new senior note facilities

* BioScrip Inc - under agreement, company entered into a $200 million first lien note facility and a $110 million second lien note facility

BRIEF-Bioscrip provides update on Unitedhealthcare contract

* Bioscrip Inc - ‍reached an agreement to continue to provide certain core product lines to unitedhealthcare beyond September 30, 2017​

Select another date: